DOCSLIB.ORG

Glucose Toler­ Ated Potassium (Kcn) Channels in Pancreatic /I-Cells

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Glucose Toler­ Ated Potassium (Kcn) Channels in Pancreatic /I-Cells PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/21830 Please be advised that this information was generated on 2021-09-27 and may be subject to change. Journal of Human Hypertension (1995) 9, 691 693 © 1995 Stockton Press, All rights reserved 0950-9240 95 $ 12.00 Do KCa channels and carbonic anhydrase play a role in thiazide-induced hyperglycaemia? P Pickkers, M Schächter, PS Sever and AD Hughes Dapartnumt of Clinical Pharmacology, Queen Elizabeth the Queen Mother Wing, St. Mary's Hospital Medical School, Imperial College of Science Technology and Medicine, South Wharf Road, London W2 I NY, UK Summary: Thiazide diuretics are widely used to treat hypertension, zides may be due to their ability to open calcium-activ but their use Is associated with impaired glucose toler­ ated potassium (KCn) channels in pancreatic /i-cells. ance. We propose that the diabetogenic action of thia­ Keywords; thiazich diiuvtica; K chuiuwl; glucose; puncwutic ß~ctrfl; calcium »*•••. ,,, «. t«r • * ■ ? •» • !< M • * ► i ß « j > * ^ *A- \ t 0Û • I * • A . \ « « , * w ^ k ^ Thiazide diuretics are a widely used therapy for cific class of ATP-dopendent potassium channels hypertension. However, glucose intolerance de­ (KATP channels) and that the consequent hyper­ velops in about 3% of hypertensive patients treated polarisation impairs insulin release,*1”11 and prob­ with thiazides.1*” The mechanism of this adverse ably accounts for the diabetogenic effect of this effect is poorly understood. Glucose intolerance drug. This effect of diazoxide can be inhibited by caused by thiazide diuretics is dose-dependent and agents such as glibenclamide which block KATP usually reversible after discontinuation of treat­ channels and are used clinically as hypoglycaemic ment.1,2 It is functionally correlated with hypokal- agents. It has also been proposed that diazoxide aemia and has been proposed to be secondary to it, exerts direct vasodilator activity by activating the In some studies prevention of the decline in serum same, or a similar, KATI> channel in vascular smooth potassium prevents hyperglycaemia- and hypokal- muscle cells.12 aemia is associated with a reduced pancreatic /i-cell Recently it has been found that hydrochlorothia­ response to glucose. However, it has also been sug­ zide also reduces insulin release. This action of gested that hypokalaemia may be an aggravating hydrochlorothiazide was associated with a fall in factor rather than a primary stimulus.J Besides the glucose-stimulated **r,Ca“+ uptake in /J-cells.^ As effect of thiazides on pancreatic cells, extra-pan­ discussed above, influx of calcium is one of the creatic; mechanisms have also been proposed to most distal steps in stinnilus-secretion coupling in explain the diabetogenic action of the thiazide pancreatic /i-cells and is crucial to insulin release.7 diuretics;1,5 We wish to propose a novel hypothesis We propose that the action of hydrochlorothiazide regarding the diabetogenic effects of thiazides based on calcium influx into the pancreatic /i-cell may be on their action on a class of potassium (K) channels, by the same mechanism by which the drug inhibits which in turn may be related to their effects on calcium entry into vascular smooth muscle cells. intracellular pH (pHj) through inhibition of car­ Our group has previously shown that hydrochloro­ bonic anhydrase. thiazide relaxes vascular smooth muscle cells In the pancreas, depolarisation of the plasma through an inhibition of calcium influx.H This ef­ membrane by closure of K channels and opening of fect of hydrochlorothiazide is associated with an cation and chloride channels leads to opening of increase in *mRb efflux, a marker of K* efflux,15 voltage-dependent calcium channels and influx of indicating that hydrochlorothiazide increases mem­ calcium,r,"a The resultant increase of intracellular brane permeability to K f ions, probably by opening calcium ([Ca2+]|) is crucial to the process of insulin K channels. The effects of hydrochlorothizide on release; drugs which interfere with these mechan­ vascular tone, [Ca2+li and miRb efflux wore inhibited isms inhibit insulin release. It is known that diazox­ by charybdotoxin, a blocker of calcium-activated ide, a drug structurally related to the thiazides, potassium (KCJ channels,UATl In contrast, the KAn> hvperpolarises pancreatic /f-cells by opening a spe- channel blocker glibenclamide did not affect hydro­ «v -* . -• -• t i A ••-•J*- *. Sv*** SÎSA *• tf' ^ < ^ 1*' “ s • • • ' / V W ' ♦ chlorothiazide-induced vasorelaxation or m’Rb ef­ Oonïïspoiultîiuut: AD Hughes flux.tn This is consistent with a previous report Kcs, and carbonic anhydrase P Pickkers et al 692 showing that hydrochlorothiazide does not affect KCa channels leads to hyperpolarisation of the cell the opening of single KATP channels in the ß-cell membrane and closure of voltage-operated calcium plasma membrane.16 These data suggest that the channels, hence [Ca“*], decreases (Figure 1). In vas­ opening of calcium activated K channels (KCû) cular smooth muscle this leads to vasodilation, rather than KATP channels mediates the vasodilator whereas in pancreatic ß-cells this leads to reduced effect of thiazides. Interestingly, electrophysiolo- insulin release and impaired glucose tolerance. gical studies have shown that cicletanine, a thia­ zide-like drug containing a furopyridine group, causes membrane hyperpolarisation in isolated Acknowledgements canine femoral arteries17 probably by an action on KCa channels. KCa channels are present in pancreatic This work was supported by the British Heart ß-cells5 and by analogy with the potassium channel Foundation and the Dutch Heart Foundation. opening properties of diazoxide it is very likely that the effect of hydrochlorothiazide on KC(l channels hyperpolarises the /3-cell membrane, leading to a References reduced insulin release. This effect could explain the inhibitory action of hydrochlorothiazide on 1 Carlsen JE et al. Relation between dose of bendroflua- insulin production. zide, anti-hypertensive effect and adverse biochemical On-going studies in our department suggest that effects. BrMed ƒ1990; 300: 975-97«. the K channel opening properties of hydrochloro­ 2 Knauf H. The role of low-dose diuretics in essential thiazide may depend on changes in intracellular pH hypertension. ƒ Cardiovasc Pharmacol 1993; 22 (pHJ. Effects of hydrochlorothiazide on pH{ appear (Suppl. 6); S1-S7. to be associated with the ability of the drug to 3 Furman BL. Impairment of glucose tolerance by inhibit carbonic anhydrase activity.18 Interestingly diuretics and other drugs. Pharmacol Thor 1981; 12: others have shown that pre-treatment with acetazo- 613—649, lamide, an inhibitor of carbonic anhydrase, caused 4 Brass EP, Effects of anti-hypertensive drugs on decreased glucose tolerance in mice and decreased endocrine function. Drugs 1984; 27: 447-458. Moore RD, Fidelman ML, Seeholzer SH, Correlation secretion of insulin by isolated pancreatic islets.lH between insulin action upon glycolysis and change in These findings support the idea that inhibition of intracellular pH. Biochem ƒ 1976; 154: 597-004, carbonic anhydrase activity may modulate pan­ 6 Sehlin J, Interrelationship between chloride fluxes in creatic ß-cell funçtion and glucose tolerance, In pancreatic islets and insulin release. Am ƒ Phvsioj addition, there are data indicating that bendro- 1978; 235: 501-508. flumethiazide, which unlike other thiazide diuret­ 7 Wollheim C, Sharp GWG. Regulation of insulin re­ ics has minimal inhibitory effects on carbonic anhy­ lease by calcium. Physiol Rev 1981; 61: 914-973. drase at therapeutic levels, does not impair glucose 8 Pederson OH, Findlay I. Electrophysiology of the pan­ tolerance in hypertensive patients20,21 and even im­ creas. Physiol Rev 1987; 67; 1054-1110, ~ proves glucose tolerance in the long term,22 9 Malaisse WJ, Malaisse-Lagae F. Effect of thiazides As a result of our studies we postulate that thia­ upon insulin secretion in vitro. Arch Int Pharmaco- dynam 1968; 171: 235-239. zide-induced hyperglucaemia is, at least in part, 10 Henquin JG, Meissner HP. Opposite «fleets of tolbuta­ due to hyperpolarisation of the /3-cell via an action mide and diazoxide on nüRb fluxes and membrane on KCa channels. This effect may be caused by potential in pancreatic /k:ells. Bioclwm Pharmacol inhibition of carbonic anhydrase by hydrochloro­ 1982; 31:1407-1415. thiazide resulting in an increase in pHi( Opening of 11 Trübe G, Roosman P, Ohno-Shusaku T. Opposite effects of tolbutamide and diazoxide on the ATP Thiazide dependent K+ channel in mouse pancreatic jU\ells. Ca2 Pfiiiger's Arch ' A K* 1986; 407: 493-499. carbonic © '12 Edwards G, Weston AH. The pharmacology of ATP- 9* anhydrase sensitive potassium channels. /Inmi Rav Pharmacol Toxicol 1993; 33: 597-637. 13 Sandstrom PE. Inhibition by hydrochlorothiazide of insulin release and calcium influx in mouse pan­ creatic /j-cells. BrJ Pharmacol 1993; 110: 1359-1362. PANCREATIC 14 Pickkers P, Hughes AD. Relaxation and decrease in ß-CELL [Ca +]i by hydrochlorothiazide in guinea pig isolated mesenteric arteries. Br ƒ Pharmacol 1995; 114: 703-707. 15 Calder JA, Schächter M, Sever PS, Potassium channel opening properties of thiazide diuretics in isolated guinea pig resistance arteries, J Cardiovasc Pharmacol 1994; 24: 158-164. Diazoxide 16 Gilles KD et al. Effect of sulfonamides on metabolite- V regulated ATP*-sensitive K* channel in rat pancreatic ------sulphonylurea 0-cells. Am J Physiol 1989; 257: 1119-1127. 17 Siegel G et al. K+ channel opening and vascular tone. Figure 1 Diagrammatic scheme illustrating the proposed In: Mulvany MJ et al (eds). Resistance Arteries» Struc­ mechanism of inhibition of insulin release by thiazides. KCil- ture and Function, pp. 130-139. Elsevier: Amster­ calcium-activated K channel, KATP-ATP-dependent K channel. dam, 1991. VOC: voltage-operated calcium channel 18 Beyer KH, Baer JE. Physiological basis for the action Kç* and carbonic anhydrase P Pickkers et al 693 of newer diuretic agents, Pharmacol Hcv 1961; 13: 21 Corcoran JS at al.
Load more

Recommended publications
  • Interactions Medicamenteuses Index Des Classes Pharmaco
    INTERACTIONS MEDICAMENTEUSES INDEX DES CLASSES PHARMACO-THERAPEUTIQUES Mise à jour avril 2006 acides biliaires (acide chenodesoxycholique, acide ursodesoxycholique) acidifiants urinaires adrénaline (voie bucco-dentaire ou sous-cutanée) (adrenaline alcalinisants urinaires (acetazolamide, sodium (bicarbonate de), trometamol) alcaloïdes de l'ergot de seigle dopaminergiques (bromocriptine, cabergoline, lisuride, pergolide) alcaloïdes de l'ergot de seigle vasoconstricteurs (dihydroergotamine, ergotamine, methylergometrine) alginates (acide alginique, sodium et de trolamine (alginate de)) alphabloquants à visée urologique (alfuzosine, doxazosine, prazosine, tamsulosine, terazosine) amidons et gélatines (gelatine, hydroxyethylamidon, polygeline) aminosides (amikacine, dibekacine, gentamicine, isepamicine, kanamycine, netilmicine, streptomycine, tobramycine) amprénavir (et, par extrapolation, fosamprénavir) (amprenavir, fosamprenavir) analgésiques morphiniques agonistes (alfentanil, codeine, dextromoramide, dextropropoxyphene, dihydrocodeine, fentanyl, hydromorphone, morphine, oxycodone, pethidine, phenoperidine, remifentanil, sufentanil, tramadol) analgésiques morphiniques de palier II (codeine, dextropropoxyphene, dihydrocodeine, tramadol) analgésiques morphiniques de palier III (alfentanil, dextromoramide, fentanyl, hydromorphone, morphine, oxycodone, pethidine, phenoperidine, remifentanil, sufentanil) analogues de la somatostatine (lanreotide, octreotide) androgènes (danazol, norethandrolone, testosterone) anesthésiques volatils halogénés
    [Show full text]
  • Extracts from PRAC Recommendations on Signals Adopted at the 9-12 March 2020 PRAC
    6 April 20201 EMA/PRAC/111218/2020 Corr2,3 Pharmacovigilance Risk Assessment Committee (PRAC) New product information wording – Extracts from PRAC recommendations on signals Adopted at the 9-12 March 2020 PRAC The product information wording in this document is extracted from the document entitled ‘PRAC recommendations on signals’ which contains the whole text of the PRAC recommendations for product information update, as well as some general guidance on the handling of signals. It can be found here (in English only). New text to be added to the product information is underlined. Current text to be deleted is struck through. 1. Immune check point inhibitors: atezolizumab; cemiplimab; durvalumab – Tuberculosis (EPITT no 19464) IMFINZI (durvalumab) Summary of product characteristics 4.4. Special warnings and precautions for use Immune-mediated pneumonitis [..] Patients with sSuspected pneumonitis should be evaluated confirmed with radiographic imaging and other infectious and disease-related aetiologies excluded, and managed as recommended in section 4.2. LIBTAYO (cemiplimab) Summary of product characteristics 1 Expected publication date. The actual publication date can be checked on the webpage dedicated to PRAC recommendations on safety signals. 2 A footnote was deleted on 8 April 2020 for the signal on thiazide and thiazide-like diuretics (see page 3). 3 A minor edit was implemented in the product information of the signal on thiazide and thiazide-like diuretics on 5 June 2020 (see page 4). Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2020.
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2005/0113314 A1 Fong Et Al
    US 20050113314A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2005/0113314 A1 Fong et al. (43) Pub. Date: May 26, 2005 (54) CICLETANINE IN COMBINATION WITH Publication Classification ORAL ANTIDIABETIC AND/OR BLOOD LIPID-LOWERING AGENTS ASA COMBINATION THERAPY FOR DIABETES (51) Int. Cl." ..................... A61K 31/70; A61K 31/4741; AND METABOLIC SYNDROME A61K 31/426; A61K 31/155; A61K 31/175 (76) Inventors: Benson M. Fong, San Francisco, CA (52) U.S. Cl. ............................ 514/25; 514/302; 514/369; (US); Glenn V. Cornett, Palo Alto, CA 514/592; 514/635 (US) Correspondence Address: KNOBBE MARTENS OLSON & BEAR LLP 2040 MAIN STREET (57) ABSTRACT FOURTEENTH FLOOR IRVINE, CA 92614 (US) Preferred embodiments of the present invention are related to novel therapeutic drug combinations and methods for (21) Appl. No.: 10/929,108 treating and/or preventing complications in patients with (22) Filed: Aug. 27, 2004 diabetes and/or metabolic Syndrome. More particularly, aspects of the present invention are related to using a Related U.S. Application Data combination of cicletanine and an oral antidiabetic agent for treating and/or preventing complications (including microal (60) Provisional application No. 60/498,916, filed on Aug. buminuria, nephropathies, retinopathies and other compli 29, 2003. cations) in patients with diabetes or metabolic Syndrome. US 2005/0113314 A1 May 26, 2005 CICLETANNE IN COMBINATION WITH ORAL women >0.85) and/or Body Mass Index >30 kg/M); 6) ANTIDIABETIC AND/OR BLOOD micro albuminuria (urine albumin excretion: 220 ugmin' LIPID-LOWERING AGENTS ASA COMBINATION or albumin/creatinine ratio22.0 mg/mmol.
    [Show full text]
  • BMJ Open Is Committed to Open Peer Review. As Part of This Commitment We Make the Peer Review History of Every Article We Publish Publicly Available
    BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available. When an article is published we post the peer reviewers’ comments and the authors’ responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to. The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript. BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (http://bmjopen.bmj.com). If you have any questions on BMJ Open’s open peer review process please email [email protected] BMJ Open Pediatric drug utilization in the Western Pacific region: Australia, Japan, South Korea, Hong Kong and Taiwan Journal: BMJ Open ManuscriptFor ID peerbmjopen-2019-032426 review only Article Type: Research Date Submitted by the 27-Jun-2019 Author: Complete List of Authors: Brauer, Ruth; University College London, Research Department of Practice and Policy, School of Pharmacy Wong, Ian; University College London, Research Department of Practice and Policy, School of Pharmacy; University of Hong Kong, Centre for Safe Medication Practice and Research, Department
    [Show full text]
  • Diuretics -August 2014
    Indian Health Service National Pharmacy and Therapeutics Committee Formulary Brief: Diuretics -August 2014- Background: The IHS National Pharmacy and Therapeutics Committee (NPTC) reviewed the diuretics class at the August 2014 meeting. The last review of this class occurred two years ago with the addition of chlorthalidone to the National Core Formulary (NCF). However, with the release of JNC 8 it was decided to review the class again to evaluate if any other modifications were necessary. The discussion included clinical, utilization and procurement data for this class of medications. This discussion did not lead to a formulary modification; however it was felt that a formulary brief would be of benefit to IHS providers. Discussion: Historically, diuretics have been the mainstay for the treatment of hypertension and the first line agent. Worldwide hydrochlorothiazide (HCTZ) is the most widely prescribed medication for blood pressure.1 The publishing of JNC 8 reinforced thiazide-type diuretics as being the first line choice for the treatment of hypertension with a review of the most current clinical studies (only RTCs were reviewed by the panel). The following is the recommendation from JNC 8 and is rated a grade B: Recommendation 6: In the general nonblack population, including those with diabetes, initial antihypertensive treatment should include a thiazide-type diuretic, calcium channel blocker (CCB), angiotensin-converting enzyme inhibitor (ACEI), or angiotensin receptor blocker (ARB). (Moderate Recommendation) The main difference between JNC 7 and JNC 8 is although thiazide-type diuretics have been show in studies to have a more potent effect at lowering blood pressure than CCB, ACEI and ARB, these agents can also be used as first line therapy depending on therapeutic necessity.
    [Show full text]
  • SUPPLEMENTARY MATERIAL 1: Search Strategy
    SUPPLEMENTARY MATERIAL 1: Search Strategy Medline search strategy 1. exp basal ganglia hemorrhage/ or intracranial hemorrhages/ or cerebral hemorrhage/ or intracranial hemorrhage, hypertensive/ or cerebrovascular disorders/ 2. ((brain$ or cerebr$ or cerebell$ or intracerebral or intracran$ or parenchymal or intraparenchymal or intraventricular or infratentorial or supratentorial or basal gangli$ or putaminal or putamen or posterior fossa or hemispher$ or pon$ or lentiform$ or brainstem or cortic$ or cortex$ or subcortic$ or subcortex$) adj5 (h?emorrhag$ or h?ematoma$ or bleed$)).tw 3. ((hemorrhag$ or haemorrhag$) adj6 (stroke$ or apoplex$ or cerebral vasc$ or cerebrovasc$ or cva)).tw 4. (ICH or ICHs or PICH or PICHs).tw 5. 1 or 2 or 3 or 4 6. exp blood pressure/ 7. exp hypertension/ 8. (blood pressure or bloodpressure).tw 9. ((bp or blood pressure) adj5 (lowering or reduc$)).tw 10. ((strict$ or target$ or tight$ or intens$ or below) adj3 (blood pressure or systolic or diastolic or bp or level$)).tw 11. (hypertension or hypertensive).tw 12. ((manage$ or monitor$) adj3 (hypertension or blood pressure)).tw 13. ((intense or intensive or aggressive or accelerated or profound or radical or severe) adj5 ((bp or blood pressure) adj5 (lowering or reduc$ or decreas$ or decrement or dimin$ or declin$))).tw 14. ((standard or normal or ordinary or guideline or guide line or guideline recommend$ or recommend$ or convention$ or usual or established) adj5 ((bp or blood pressure) adj5 (lowering or reduc$ or decreas$ or decrement or dimin$ or declin$))).tw 15. (antihypertensive adj2 (agent$ or drug$ or medicat$)).tw 1 16. 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 17.
    [Show full text]
  • Diuretics in the Treatment of Patients Who Present Congestive Heart Failure and Hypertension
    Journal of Human Hypertension (2002) 16 (Suppl 1), S104–S113 2002 Nature Publishing Group All rights reserved 0950-9240/02 $25.00 www.nature.com/jhh Diuretics in the treatment of patients who present congestive heart failure and hypertension AJ Reyes Institute of Cardiovascular Theory, Montevideo, Uruguay The main operational objective of diuretic therapy in ment natriuresis in patients with congestive heart failure patients who present congestive heart failure and hyper- and hypertension. The state of renal function, the exis- tension is to reduce or to suppress excess bodily fluid. tence of certain co-morbid conditions, potential Effective diuretic therapy decreases cardiac size when untoward drug actions, and possible interactions of the heart is dilated, and it reduces lung congestion and diuretics with nutrients and with other drugs are some excess water. Consequently, external respiratory work of the factors that must be considered at the time of diminishes and cardiac output would be redistributed in deciding on the diuretic drug(s) and dose(s) to be pre- favour of systemic vascular beds other than that of the scribed. Spironolactone has been found to increase life respiratory muscles; dyspnoea decreases markedly and expectancy and to reduce hospitalisation frequency there is a slight reduction in fatigue. This clinical when added to the conventional therapeutic regimen of improvement and the fall in body weight caused by patients with advanced congestive heart failure and sys- diuretics entail an increase in effort capacity. Sub- tolic dysfunction. Therefore, spironolactone should be sequent exercise training ameliorates the abnormal ven- the drug of choice to oppose the kaliuretic effect of a tilatory response to physical effort and the skeletal mus- loop or of a thiazide-type diuretic.
    [Show full text]
  • Glucose Toler­ Ated Potassium (Kcn) Channels in Pancreatic /I-Cells
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Radboud Repository PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/21830 Please be advised that this information was generated on 2017-12-05 and may be subject to change. Journal of Human Hypertension (1995) 9, 691 693 © 1995 Stockton Press, All rights reserved 0950-9240 95 $ 12.00 Do KCa channels and carbonic anhydrase play a role in thiazide-induced hyperglycaemia? P Pickkers, M Schächter, PS Sever and AD Hughes Dapartnumt of Clinical Pharmacology, Queen Elizabeth the Queen Mother Wing, St. Mary's Hospital Medical School, Imperial College of Science Technology and Medicine, South Wharf Road, London W2 I NY, UK Summary: Thiazide diuretics are widely used to treat hypertension, zides may be due to their ability to open calcium-activ but their use Is associated with impaired glucose toler­ ated potassium (KCn) channels in pancreatic /i-cells. ance. We propose that the diabetogenic action of thia­ Keywords; thiazich diiuvtica; K chuiuwl; glucose; puncwutic ß~ctrfl; calcium »*•••. ,,, «. t«r • * ■ ? •» • !< M • * ► i ß « j > * ^ *A- \ t 0Û • I * • A . \ « « , * w ^ k ^ Thiazide diuretics are a widely used therapy for cific class of ATP-dopendent potassium channels hypertension. However, glucose intolerance de­ (KATP channels) and that the consequent hyper­ velops in about 3% of hypertensive patients treated polarisation impairs insulin release,*1”11 and prob­ with thiazides.1*” The mechanism of this adverse ably accounts for the diabetogenic effect of this effect is poorly understood.
    [Show full text]
  • Use of Isoindoles for the Treatment of Neurobehavioral Disorders
    (19) TZZ¥_Z¥_T (11) EP 3 156 053 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 19.04.2017 Bulletin 2017/16 A61K 31/4035 (2006.01) A61P 25/00 (2006.01) (21) Application number: 16200855.1 (22) Date of filing: 04.06.2009 (84) Designated Contracting States: (72) Inventors: AT BE BG CH CY CZ DE DK EE ES FI FR GB GR • KOVACS, Bruce HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL Long Beach, CA California 90803 (US) PT RO SE SI SK TR • PINEGAR, Laura Long Beach, CA California 90803 (US) (30) Priority: 20.06.2008 US 74500 (74) Representative: Petty, Catrin Helen et al (62) Document number(s) of the earlier application(s) in Venner Shipley LLP accordance with Art. 76 EPC: 200 Aldersgate 09767450.1 / 2 307 011 London EC1A 4HD (GB) (71) Applicant: Afecta Pharmaceuticals, Inc. Remarks: Irvine, CA 92612 (US) This application was filed on 28-11-2016 as a divisional application to the application mentioned under INID code 62. (54) USE OF ISOINDOLES FOR THE TREATMENT OF NEUROBEHAVIORAL DISORDERS (57) The present invention generally relates to the disorder and/or treatment or prevention of symptoms of use of drugs for the treatment of neurobehavioral disor- a neurobehavioral disorder by administering suitable Iso- ders or symptoms of a neurobehavioral disorder associ- indole derivatives alone or in combination with other ated with dysfunction of the trimonoamine modulating agents so as to provide relatively equal inhibitory effect system (TMMS). More specifically, the invention de- on serotonin, dopamine and norepinephrine transport- scribes methods for the treatment of a neurobehavioral ers.
    [Show full text]
  • Anatomical Classification Guidelines V2018 EPHMRA ANATOMICAL
    EPHMRA ANATOMICAL CLASSIFICATION GUIDELINES 2018 Anatomical Classification Guidelines V2018 "The Anatomical Classification of Pharmaceutical Products has been developed and maintained by the European Pharmaceutical Marketing Research Association (EphMRA) and is therefore the intellectual property of this Association. EphMRA's Classification Committee prepares the guidelines for this classification system and takes care for new entries, changes and improvements in consultation with the product's manufacturer. The contents of the Anatomical Classification of Pharmaceutical Products remain the copyright to EphMRA. Permission for use need not be sought and no fee is required. We would appreciate, however, the acknowledgement of EphMRA Copyright in publications etc. Users of this classification system should keep in mind that Pharmaceutical markets can be segmented according to numerous criteria." EphMRA 2018 Anatomical Classification Guidelines V2018 CONTENTS PAGE INTRODUCTION A ALIMENTARY TRACT AND METABOLISM 1 B BLOOD AND BLOOD FORMING ORGANS 28 C CARDIOVASCULAR SYSTEM 35 D DERMATOLOGICALS 50 G GENITO-URINARY SYSTEM AND SEX HORMONES 59 H SYSTEMIC HORMONAL PREPARATIONS (EXCLUDING SEX HORMONES) 67 J GENERAL ANTI-INFECTIVES SYSTEMIC 71 K HOSPITAL SOLUTIONS 87 M MUSCULO-SKELETAL SYSTEM 104 N NERVOUS SYSTEM 109 P PARASITOLOGY 119 R RESPIRATORY SYSTEM 121 S SENSORY ORGANS 132 T DIAGNOSTIC AGENTS 139 V VARIOUS 142 Anatomical Classification Guidelines V2018 INTRODUCTION The Anatomical Classification was initiated in 1971 by EphMRA. It has been developed jointly by PBIRG and EphMRA. It is a subjective method of grouping certain pharmaceutical products and does not represent any particular market, as would be the case with any other classification system. These notes are known as the Anatomical Classification Guidelines, and are intended to be used in conjunction with the classification.
    [Show full text]
  • A Phase 2, Randomized, Double-Blind, Placebo-Controlled
    FINAL CLINICAL STUDY REPORT Study Title: A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects with Pulmonary Arterial Hypertension Name of Test Drug: Cicletanine hydrochloride Dose and Formulation: Cicletanine HCl oral capsules Doses: 150 and 300 mg once daily (qd), 150 mg twice daily (bid) Indication: Pulmonary arterial hypertension (PAH) Sponsor: Gilead Sciences, Inc. 333 Lakeside Drive Foster City, CA 94404 USA Study No.: GS-US-235-0101 Phase of Development: Phase 2 IND No.: 32,283 EudraCT No.: 2008-007455-26 Study Start Date: 16 March 2009 (First subject screened) Study End Date 22 February 2012 (Last subject observation) Principal or Coordinating Name: Aaron B. Waxman, MD, PhD Investigator: Affiliation: PPD Telephone: PPD Fax: PPD Gilead Responsible Medical Name: Hunter Gillies Monitor: Telephone: PPD Fax: PPD Report Date: 22 August 2012 CONFIDENTIAL AND PROPRIETARY INFORMATION This study was conducted in accordance with the guidelines of Good Clinical Practice, including archiving of essential documents. Cicletanine Hydrochloride Study GS-US-235-0101 Final Clinical Study Report Final STUDY SYNOPSIS Study GS-US-235-0101: Gilead Sciences, Inc. 333 Lakeside Drive Foster City, CA 94404 USA Title of Study: Study GS-US-235-0101 Investigators: Multicenter Study Centers: 42 sites in 9 countries (Australia, Austria, Canada, Germany, Israel, Mexico, Spain, United Kingdom [UK], and United States [US]) Publications: Waxman A, Oudiz R, Shapiro S, Gomberg-Maitland M, Keogh A, Badesch D, Frantz R, Gregory Elliott C, Gillies H, Walker G. Cicletanine in pulmonary arterial hypertension (PAH): Results from a phase 2 randomized placebo-controlled trial.
    [Show full text]